EUROPEAN COMMISSION
HEALTH AND FOOD SAFETY DIRECTORATE-GENERAL

Health systems, medical products and innovation
Performance of national health systems

Expert Panel on Effective Ways of Investing in Health

1th Working Group meeting on
Innovative payment models for high-cost innovative medicines

B232 08/78
Monday 13 March 2017, 16:00 – 17:30 h CET
Audio conference

MINUTES

1. Participants

1.1. Members	Walter Ricciardi (WR)	Chair
	Pedro Pita Barros PPB)	Rapporteur
	Aleš Bourek (AB)	
	Werner Brouwer (WB)	Apologies
	Lasse Lehtonen (LL)	
	Martin McKee (MMK)	
	Claudia Wild (CW)	
1.2. Secretariat	Dimitris Florinis (DM)	
	Päivi Kontinen (PK)	

2. Welcome and apologies

WR opened the meeting and welcomed the participants. Apologies were received from Werner Brouwer.

3. On-going work on the opinion

Summary of work so far

PPB outlined the mandate received from COM and opened the discussion on the three main groups of questions mentioned under the Terms of Reference.

(a) What is the current role of the national pricing and reimbursement authorities to improve access on innovative medicines? Is there a scope to explore new ways of setting prices for specialty medicines in terms of improving access, while taking in to account the costs, the benefits, the budget impact and the future return on investment on a transparent way? How to deal with polypharmacy/ combination of treatments? What are the existing frameworks for such dynamic payment models? Any experience from other economy sectors (transport or telecommunications) that can potentially be applied to medicines?

(b) How can the use and uptake of medicines impact the health care costs? Can this be reflected on price setting ie reward for the right behaviour? Ways to monitor the adherence to treatment? What is the importance of choosing the right outcomes to measure the performance? What is the role of RWD for innovative payment models and are there any prerequisites to develop such system? Is it possible to develop a common definition for RWD from all different perspectives (regulators, HTA bodies, payers, pharmacovigilance etc)?

(c) Is there a theoretical framework for the interpretation of the results and outcomes? Is there a framework of health system performance assessment in the area of pharmaceuticals and possible areas for future work? Is there a scope to improve resilience and cooperation between those bodies that are involved in the decision making process? What type of synergies can be developed between the payers, HTA bodies and regulators in the EU?

Each question was discussed and reflected on in particular from the point of view of whether additional information was needed and which WG member could contribute to the various parts.

The question "Ways to monitor the adherence to treatment?" was considered not relevant for the time being. All other points were deemed necessary for the Opinion.

Action points:

1. PPB will receive comments from the WG members.

2. PPB will revise the draft outline by the end of the week.

3.1. Practical arrangements

The next WG meeting will take place on Monday in Brussels on Monday 20.3.2017 when the discussion on the drafting of the opinion will continue.